HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infirst Launches GSL Version Of Flarin Lipid Ibuprofen In UK

Executive Summary

Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand. 

You may also be interested in...



Flarin’s Philip Lindsell: UK ITV Backing Could Provide Springboard For International Expansion

Flarin Holdings recently secured £5m ($6.2m) investment from UK television company ITV's Media for Equity fund in return for a minority stake in the company, which markets analgesic brand Flarin in the UK. The investment could be a springboard for international expansion, including in the US, Flarin's managing director Philip Lindsell tells HBW Insight in an exclusive in-depth interview.

EU Business News: Probi Offers Dairy-Free Probiotic, Infirst Expands Flarin Reach, Clasado Eyes French Market

A round-up of the latest European consumer health business news: Sweden's Probi preparing to roll-out dairy-free probiotic; Infirst expands UK distribution of Flarin ibuprofen; and Clasado strikes deal to take prebiotic ingredient to France.

EU Business Round-Up: Mayoly Spindler Acquires Biohealth, Flarin Gets Funding, Karo Ready For M&A

The latest European consumer health business news: France's Mayoly Spindler acquires Italian supplements specialist Biohealth; UK-based Flarin gets funding to expand at home and abroad; and Sweden's Karo plots further M&A in 2021.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel